SuperworthNovoCure price to free cash flow NVCR
Market value divided by free cash flow over the last twelve months, since 2019.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 451×
- Feb 2023
- 7-year median
- 278×
- 7-year range
- 61.5× to 484×
- Peer median
- 28.1×
NovoCure's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.
It was last meaningful in Feb 2023, at 451×.
On the days it had one over the last 7 years, its median was 278×, from 61.5× in Jan 2022 to 484× in Jan 2023.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2023 | 451× | 451× | 484× |
| 2022 | 391× | 61.5× | 438× |
| 2021 | 73.4× | 73.4× | 480× |
| 2020 | 436× | 246× | 469× |
| 2019 | 287× | 247× | 381× |
Against its peers
Companies in Medical - Instruments & Supplies nearest NovoCure's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| NVCRNovoCure | n/m |
| LMATLemaitre Vascular | 26.2× |
| EYENational Vision | 30.1× |
| INSPInspire Medical Systems | 17.6× |
| CDRECadre | 16.4× |
| UFPTUFP Technologies | n/m |
| BVSBioventus | 13.3× |
| STAAStaar Surgical | n/m |
| IRMDIradimed | 43.7× |
| ATRCAtriCure | 56.5× |
| WRBYWarby Parker | 147× |
| Peer median | 28.1× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on NovoCure
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.